<DOC>
	<DOCNO>NCT02531516</DOCNO>
	<brief_summary>The purpose study determine apalutamide plus gonadotropin release hormone ( GnRH ) agonist participant high-risk , localize locally advanced prostate cancer receive primary radiation therapy result improvement metastasis-free survival .</brief_summary>
	<brief_title>An Efficacy Safety Study JNJ-56021927 ( Apalutamide ) High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy : ATLAS</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter study apalutamide plus GnRH agonist compare GnRH agonist among participant high-risk , localize locally advanced prostate cancer receive primary radiation therapy ( RT ) . The study include Screening Phase , Treatment Phase , Posttreatment Phase , Long-term Follow-up Phase . Participants either receive either apalutamide ( experimental ) bicalutamide 50 milligram ( mg ) capsule plus placebo control group . Safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Age &gt; = 18 year Indicated planned receive primary radiation therapy prostate cancer Histologically confirm adenocarcinoma intact prostate , 1 follow diagnosis : 1 ) Gleason score &gt; =8 &gt; =cT2c , 2 ) Gleason score &gt; =7 , PSA &gt; =20 nanogram per milliliter ( ng/mL ) , &gt; =cT2c Charlson index ( CCI ) &lt; =3 An Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) grade 0 1 Adequate organ function : ( 1 ) aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , within normal limit ( WNL ) , ( 2 ) serum creatinine less ( &lt; ) 1.5 milligram/deciliter ( mg/dL ) ( &lt; 133 micromoles/Liter [ mcmol/L ] ) , ( 3 ) platelet great equal ( &gt; = ) 140,000/microLiter ( mcL ) , independent transfusion and/or growth factor within 3 month prior randomization , ( 4 ) Hemoglobin &gt; = 12.0 gram/deciliter ( g/dL ) ( 7.4 millimloes [ mmol ] , independent transfusion and/or growth factor within 3 month prior randomization Participants sexually active ( even men vasectomy ) willing use condom agree donate sperm trial Signed , write , inform consent Be able swallow whole study drug tablet Presence distant metastasis , ( clinical stage M1 ) . Isolated pelvic nodal disease iliac bifurcation ( clinical stage N1 ) exclusion . Diagnosis distant metastasis ( clinical M stage ; M0 versus M1a , M1b , M1c ) pelvic nodal disease ( clinical N stage ; N1 versus N0 ) assess central radiological review . Patients consider eligible central radiological review confirm clinical stage M0 . Prior treatment gonadotropin release hormone ( GnRH ) analogue antiandrogen &gt; 3 month prior randomization Bilateral orchiectomy History pelvic radiation Prior systemic ( example [ e.g . ] , chemotherapy ) local ( e.g . radical prostatectomy , cryotherapy ) treatment prostate cancer History seizure condition may predispose seizure ( include , limited prior stroke , transient ischemic attack loss consciousness &lt; = 1 year prior randomization ; brain arteriovenous malformation ; intracranial mass schwannomas meningiomas cause edema mass effect ) Prior treatment enzalutamide , abiraterone acetate , orteronel , galeterone , ketoconazole , aminoglutethimide , estrogen , megestrol acetate , progestational agent ( include cyproterone acetate ) prostate cancer Prior treatment radiopharmaceutical agent ( e.g. , strontium89 ) immunotherapy ( e.g. , sipuleucelT ) prostate cancer Prior treatment systemic glucocorticoid â‰¤4 week prior randomization expect require longterm use corticosteroid study Use 5alpha reductase inhibitor ( e.g. , dutasteride , finasteride ) &lt; =4 week prior randomization Use investigational agent &lt; =4 week prior randomization Current chronic use opioid analgesic &gt; =3 week oral &gt; 7 day nonoral formulation Major surgery &lt; =4 week prior randomization Current prior treatment antiepileptic medication treatment seizures Gastrointestinal condition affect absorption Known suspect contraindication hypersensitivity apalutamide , bicalutamide GnRH agonists component formulation Any condition , opinion investigator , participation would best interest subject</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>High-Risk prostate cancer</keyword>
	<keyword>JNJ-56021927</keyword>
	<keyword>Apalutamide</keyword>
	<keyword>ATLAS</keyword>
	<keyword>Radiation</keyword>
	<keyword>Long-term hormone therapy</keyword>
	<keyword>Localized locally advanced prostate cancer</keyword>
	<keyword>Janssen</keyword>
</DOC>